Protagonist Therapeutics (PTGX) Stock Statistics & Valuation Metrics

Protagonist Therapeutics has a market cap or net worth of $3.51B. The enterprise value is $3.30B.

Protagonist Therapeutics has 61,981,956 shares outstanding. The number of shares has decreased by -2.65% in one year.

Protagonist Therapeutics’s return on equity (ROE) is 0.41 and return on invested capital (ROIC) is 35.69%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Protagonist Therapeutics had revenue of 434.43M and earned 275.19M in profits. Earnings per share was 4.47.

In the last 12 months, operating cash flow was 336.94M and capital expenditures -1.66M, giving a free cash flow of 335.29M billion.

Protagonist Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Protagonist Therapeutics upcoming earnings date is Jul 31, 2025, After Close (Confirmed).

Protagonist Therapeutics as a current ratio of 12.48, with Debt / Equity ratio of 1.65%

In the past 12 months, Protagonist Therapeutics has paid 4.22M in taxes.

Protagonist Therapeutics EV to EBITDA ratio is 9.06, with an EV/FCF ratio of 12.53.

Protagonist Therapeutics has $574.36M in cash and marketable securities with $11.36M in debt, giving a net cash position of -$563.00M billion.

Gross margin is 99.28%, with operating margin of 58.20%, and net profit margin of 63.34%.

The average price target for Protagonist Therapeutics is $71.13, which is 11.43% higher than the current price. The consensus rating is Strong Buy